A-443654 is a pan-Akt inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
IC50&Target
Akt1
160 pM (Ki)
Akt2
160 pM (Ki)
Akt3
160 pM (Ki)
PKA
6.3 nM (Ki)
PKCγ
24 nM (Ki)
PKCδ
33 nM (Ki)
KDR
3.1 μM (Ki)
cKIT
1.2 μM (Ki)
SRC
2.6 μM (Ki)
Flt1
3.6 μM (Ki)
CDK2
24 nM (Ki)
ERK2
340 nM (Ki)
GSK3β
41 nM (Ki)
CK2
2.4 μM (Ki)
Chk1
2.3 μM (Ki)
RSK2
11 nM (Ki)
MAPK-AP2
3.3 μM (Ki)
体外研究
A-443654 exhibits a Ki of 160 pM, a 30,000-fold improvement in potency versus the initial lead molecule. A-443654 is 40-fold selective for Akt over PKA. A-443654 inhibits Akt1, Akt2, or Akt3 equally within cells. A-443654 reduces the P-GSK3 in a dose-responsive manner in all three cell lines. A-443654 inhibits the proliferation of tumor cells with EC50 of 0.1 μM. A-443654-induced morphological changes occur very rapidly (within 2 to 4 h) in both 10A and 10CA1a cells, with 10CA1a cells more sensitive to A-443654 than the 10A cells. A-443654 alone at 2 μM causes the 10CA1a cells, but not the 10A cells, to detach from the plate after 12 h, whereas 1 μM of A-443654 causes 10CA1a cells to detach from the plate after 12 h. FACScan Analysis of rapamycin and A-443654 effects on DNA content in 10A and 10CA1a cells. In contrast, A-443654 at 2 and 5 μM decreases Bcl-2 levels by 30 to 40% in the 10CA1a cells at 8h. The combination of rapamycin with 2 or 5 μM A-443654, however, markedly decreases Bcl-2 protein levels by appr 40 to 50% in the 10A cells and by appr 70% in the 10CA1a cells, respectively. A-443654 demonstrates the greatest selective effect on the mutant cells compared to the WT cells with greater than 3.5 fold relative growth inhibition of the mutant cells.
体内研究
A-443654 (7.5 mg/kg/d, s.c.) inhibits tumor growth in the 3T3-Akt1 flank tumor model. A-443654 (50 mg/kg, s.c.) induces apoptosis in 3T3-Akt1 flank tumors. A-443654 (30 mg/kg, s.c.) leads to increased levels of phosphorylated Akt1 in MiaPaCa-2 tumors.
分子式
C24H23N5O
分子量
397.47
CAS号
552325-16-3
运输条件
Room temperature in continental US; may vary elsewhere.